{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.663","value":"52.11"},{"groupId":"OG001","spread":"21.543","value":"104.82"},{"groupId":"OG002","spread":"38.528","value":"142.83"},{"groupId":"OG003","spread":"7.651","value":"21.93"},{"groupId":"OG004","spread":"17.314","value":"49.00"},{"groupId":"OG005","spread":"6.890","value":"104.47"},{"groupId":"OG006","spread":"8.825","value":"124.36"},{"groupId":"OG007","spread":"16.750","value":"85.45"},{"groupId":"OG008","spread":"25.708","value":"93.41"},{"groupId":"OG009","spread":"23.406","value":"93.69"},{"groupId":"OG010","spread":"37.646","value":"83.01"},{"groupId":"OG011","spread":"17.451","value":"81.40"},{"groupId":"OG012","spread":"23.863","value":"102.62"},{"groupId":"OG013","spread":"22.209","value":"87.42"},{"groupId":"OG014","spread":"18.816","value":"103.09"},{"groupId":"OG015","spread":"13.515","value":"92.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"29"},{"groupId":"OG010","value":"27"},{"groupId":"OG011","value":"63"},{"groupId":"OG012","value":"30"},{"groupId":"OG013","value":"30"},{"groupId":"OG014","value":"26"},{"groupId":"OG015","value":"10"}],"units":"Participants"}],"title":"Cmax Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.223","value":"2.68"},{"groupId":"OG001","spread":"17.127","value":"28.61"},{"groupId":"OG002","spread":"18.490","value":"37.08"},{"groupId":"OG003","spread":"4.414","value":"3.29"},{"groupId":"OG004","spread":"2.711","value":"3.96"},{"groupId":"OG005","spread":"16.098","value":"25.57"},{"groupId":"OG006","spread":"5.307","value":"28.76"},{"groupId":"OG007","spread":"8.351","value":"10.34"},{"groupId":"OG008","spread":"10.176","value":"16.22"},{"groupId":"OG009","spread":"10.054","value":"17.82"},{"groupId":"OG010","spread":"6.959","value":"13.65"},{"groupId":"OG011","spread":"9.663","value":"15.45"},{"groupId":"OG012","spread":"12.496","value":"25.07"},{"groupId":"OG013","spread":"9.111","value":"14.19"},{"groupId":"OG014","spread":"16.282","value":"31.96"},{"groupId":"OG015","spread":"12.316","value":"17.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"29"},{"groupId":"OG010","value":"27"},{"groupId":"OG011","value":"63"},{"groupId":"OG012","value":"30"},{"groupId":"OG013","value":"30"},{"groupId":"OG014","value":"26"},{"groupId":"OG015","value":"10"}],"units":"Participants"}],"title":"Cmin Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG006","spread":"63.438","value":"187.27"},{"groupId":"OG008","spread":"39.937","value":"126.01"},{"groupId":"OG009","spread":"44.856","value":"142.85"},{"groupId":"OG010","spread":"25.252","value":"97.24"},{"groupId":"OG011","spread":"24.249","value":"108.76"},{"groupId":"OG012","spread":"29.845","value":"130.17"},{"groupId":"OG013","spread":"40.392","value":"121.06"},{"groupId":"OG014","spread":"47.960","value":"167.66"},{"groupId":"OG015","spread":"15.283","value":"164.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"8"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"8"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"4"}],"units":"Participants"}],"title":"Cmax Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG006","spread":"58.420","value":"109.66"},{"groupId":"OG008","spread":"20.999","value":"38.79"},{"groupId":"OG009","spread":"6.642","value":"52.26"},{"groupId":"OG010","spread":"13.674","value":"37.05"},{"groupId":"OG011","spread":"11.189","value":"40.63"},{"groupId":"OG012","spread":"15.291","value":"36.95"},{"groupId":"OG013","spread":"16.612","value":"40.15"},{"groupId":"OG014","spread":"30.039","value":"85.33"},{"groupId":"OG015","spread":"12.572","value":"82.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"8"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"8"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"4"}],"units":"Participants"}],"title":"Cmin Cycle 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"27"},{"groupId":"OG009","value":"29"},{"groupId":"OG010","value":"27"},{"groupId":"OG011","value":"63"},{"groupId":"OG012","value":"30"},{"groupId":"OG013","value":"30"},{"groupId":"OG014","value":"26"},{"groupId":"OG015","value":"10"}],"units":"Participants"}],"description":"Cabiralizumab serum concentration was determined using a validated enzyme-linked immunosorbent assay method.\n\nCmax is the maximum observed serum concentration of cabiralizumab during the dosing period.\n\nCmin is the minimum observed serum concentration of cabiralizumab during a dosing interval (excluding pre-dose concentration before the first dose).","dispersionType":"Standard Deviation","groups":[{"description":"Participants with any solid tumor received 2 mg/kg cabiralizumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG000","title":"Cabiralizumab 2 mg/kg Q2W"},{"description":"Participants with any solid tumor received 4 mg/kg cabiralizumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG001","title":"Cabiralizumab 4 mg/kg Q2W"},{"description":"Participants with any solid tumor received 6 mg/kg cabiralizumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG002","title":"Cabiralizumab 6 mg/kg Q2W"},{"description":"Participants with any solid tumor received 1 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG003","title":"Cabiralizumab 1 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants with any solid tumor received 2 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG004","title":"Cabiralizumab 2 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants with any solid tumor received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG005","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants with any solid tumor received 6 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG006","title":"Cabiralizumab 6 mg/kg + Nivolumab 3 mg/kg Q2W"},{"description":"Participants with any solid tumor received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q3W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG007","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q3W"},{"description":"Participants with NSCLC with no prior exposure to any PD-1 pathway targeting drug (PD-1 naïve) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG008","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Naïve)"},{"description":"Participants with NSCLC with de novo or acquired resistance to an anti-PD-1 targeting drug (PD-1 resistant) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG009","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Resistant)"},{"description":"Participants with SCCHN received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG010","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: SCCHN"},{"description":"Participants with pancreatic cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG011","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Pancreatic Cancer"},{"description":"Participants with advanced ovarian cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG012","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Ovarian Cancer"},{"description":"Participants with RCC received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG013","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: RCC"},{"description":"Participants with malignant glioma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG014","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: GBM"},{"description":"Participants with melanoma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG015","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Melanoma"}],"paramType":"MEAN","populationDescription":"The PK evaluable population included participants who received at least 1 dose of cabiralizumab, had at least 1 available serum concentration data, and adequate PK assessments which could be used to reliably derive at least 1 PK parameter. Not all participants completed 8 cycles.\n\nPK data are reported by treatment regimen for Phase 1a participants and by disease type for Phase 1b participants.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 8, Day 1 predose, and at 0.25, 4, 24, 72, 168, and 336 hours after the end of infusion.","title":"PK of Cabiralizumab: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin)","type":"SECONDARY","unitOfMeasure":"µg/mL"}